Request Call Back

Contact Us

No Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Please describe your case:

Date of Incident : 

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


We Are Presently Not Accepting Zyprexa Diabetes Cases
We Are Presently Not Accepting Zyprexa Diabetes Cases

Zyprexa Side Effects Could Be Linked To Diabetes, Deadly Heart Risk, Torsades de Pointes

Zyprexa Side Effects Could Be Linked To Diabetes, Deadly Heart Risk, Torsades de Pointes

Zyprexa Side Effects Could Be Linked To Diabetes, Deadly Heart Risk, Torsades de Pointes

Recently, Zyprexa has been linked to an increased risk of Torsades de Pointes, a potentially fatal abnormality in the heart rhythm. Torsades de Pointes occurs when the bottom chambers of the heart beat too quickly; this prevents blood from being pumped to the brain and the patient often loses consciousness. If not corrected right away, this can lead to a ventricular fibrillation (where the heart essentially stops pumping blood) and death. In April 2013, Drug Safety published a study showing that Zyprexa and two other antipsychotic medications were associated with a higher risk for Torsades de Pointes. Using the FDA’s Adverse Events Reporting System (AERS), researchers identified 450 cases of QT interval abnormalities (meaning that heart cells take a long time to recharge), 41 cases of Torsades de Pointes, 2,971 cases of cardiac arrhythmia and 943 instances of cardiac death between November 1997 and August 2012 where Zyprexa was listed as a suspect drug.

Eli Lilly and Co. announced on June 9, 2005 that it has entered into an agreement in principle to settle about 8,000, or 75%, of the claims against the company related to its schizophrenia medication, Zyprexa.  The agreement involves claimants who asserted they developed diabetes-related conditions from their use of Zyprexa.

The popular schizophrenia drug Zyprexa has been linked to serious side effects including diabetes, hyperglycemia and other blood sugar disorders. The FDA has asked Eli Lilly, the manufacturer or Zyprexa, to add a new warning to the drug, warning patients of these side effects.

In a recent study, Zyprexa and two other atypical antipsychotics that are used to treat schizophrenia were found to cause diabetes 50 percent more often than older drugs.

Last year, Britain's Medicines Control Agency warned that several patients taking Eli Lilly's top selling drug Zyprexa (used to treat schizophrenia) had developed diabetes-related complications. In the Medicine Control Agency's Current Problems newsletter, the regulatory body said that the antipsychotic drug "can adversely affect blood glucose."

Forty reports "of hyperglycemia (elevated blood sugar), diabetes mellitus, or exacerbation of diabetes have been received in the UK. Four were associated with ketoacidosis and/or coma including one with a fatal outcome," according to the newsletter. "The precise mechanism of this suspected adverse drug reaction has not yet been elucidated and is currently being investigated further.

This follows an emergency report issued in April 2002 by the Japanese Health and Welfare Ministry to Eli Lilly Japan KK concerning side effects of Zyprexa after the deaths of two diabetic users of the drug. It said seven other patients had lost consciousness or become comatose after taking the drugs in the last 10 months.

The Japanese Ministry said no new diabetes patients should be treated with the drug and ordered Eli Lilly to warn doctors to closely monitor diabetics already on the medication.

A paper written in late 2001 in the Journal of Clinical Psychiatry reports the FDA has been alerted 19 case reports of diabetes associated with the use of Zyprexa. Of the 19 patients seven had newly diagnosed hyperglycemia. The sugar disorder developed within a week of taking Zyprexa in two patients and within six months for eight others. One patient ultimately died of necrotizing pancreatitis, a condition in which cells in the pancreas die.

On April 11, 2005, the FDA announced that older patients with dementia who are given antipsychotic medicines are far more likely to die prematurely than those given dummy pills. The warning adds to growing worries about the safety of the widely prescribed drugs. The Food and Drug Administration said that it would now require manufacturers of the medicines to place black-box warnings the agency's most severe on the labels of all the drugs.

Zyprexa and Symbyax from Eli Lilly, Risperdal from Johnson & Johnson, Seroquel from AstraZeneca, Abilify from Bristol-Myers Squibb, Clozaril from Novartis and Geodon from Pfizer are all affected by the warning.

Legal Help For Victims Affected By Zyprexa

If you or a loved one were affected by Zyprexa, please fill out the form at the right for a free case evaluation by a qualified attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).


ZyprexaRSS Feed

Antipsychotic Drugs' Effects On Kids Need More Study, FDA Panel Says

Dec 7, 2009 | Parker Waichman LLP
We’ve been following the issue of prescribing psychotropic drugs to pediatric patients for some time, especially regarding efficacy and safety. In June we wrote that a U.S. Food and Drug Administration (FDA) vote was scheduled regarding three psychotropic medications and their safety and efficacy for children with specific conditions.At that time, the Wall Street Journal reported that the agency said the medications—AstraZeneca PLC’s Seroquel, Eli Lilly and Company’s...

More Worries Over Zyprexa, Seroquel, Other Antipsychotics

Dec 2, 2009 | Parker Waichman LLP
Some antipsychotic medications, including Zyprexa and Seroquel, have been linked to a variety of adverse health reactions including weight gain, hyperglycemia, and hyperlipidemia. Science Daily reports that the current issue of the journal Biological Psychiatry, published by Elsevier, contains a piece in which researchers write about metabolic side effects linked to some antipsychotics and how these effects can increase risks for cardiac-related diseases such as diabetes and hypertension.One...

Atypical Antipsychotics Linked to Worrisome Weight Gains, Other Outcomes, in Children

Oct 28, 2009 | Parker Waichman LLP
Yet another study has linked significant weight gains in children to some antipsychotic medication. Forbes reported that an emerging study found that weight gains of 10-to-20 pounds were not unusual in children during their first three months on the medications like Zyprexa, Seroquel, Risperdal and Abilify. Also, cholesterol, triglyceride, and other metabolic “parameters” were elevated, said Forbes.It has long been known and we have long written about the association between weight...

Eli Lilly Reaches Zyprexa Settlement with West Virginia

Aug 21, 2009 | Parker Waichman LLP
Drug maker Eli Lilly has agreed to another multimillion dollar Zyprexa settlement, this time with the state of West Virginia.  According to, the $22.5 million settlement resolves the state's clams that the company improperly marketed Zyprexa.  West Virginia was seeking reimbursement for Medicaid money spent on the drug.Eli Lilly still faces other lawsuits filed by states that claim Zyprexa was marketed for unapproved uses, such as dementia and depression.  These...

Zyprexa Articles Ghostwritten

Jun 12, 2009 | Parker Waichman LLP
Zyprexa maker Eli Lilly apparently asked doctors to put their names on articles written by company officials in an effort to promote the drug.  According to, the company's alleged strategy to use ghostwritten articles to increase Zyprexa sales was revealed when more than 10,000 pages of internal documents were unsealed last month in lawsuits that allege Eli Lilly exaggerated  the drug's  effectiveness.According to a report, Zyprexa is Eli Lilly's...

More Zyprexa News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo